摘要
Traditional drug discovery mainly focuses on direct regulation of protein activity.The development and application of protein activity modulators,particularly inhibitors,has been the mainstream in drug development.In recent years,PROteolysis TArgeting Chimeras(PROTAC)technology has emerged as one of the most promising approaches to remove specific disease-associated proteins by exploiting cells’own destruction machinery.In addition to PROTAC,many different targeted protein degradation(TPD)strategies including,but not limited to,molecular glue,Lysosome-Targeting Chimaera(LYTAC).
基金
Research in the authors’laboratory is supported by Natural Science Foundation of China(NSFC)grants(#91854121,#31871429,#82073404)
National Science Fund for Distinguished Young Scholars(32125012)
National Key R&D Program of China(2018YFC1005004)
Sichuan Science and Technology Program(2018RZ0128)
special research fund on COVID-19 of West China Hospital(HX-2019-nCoV-064).
